16 December 2025 : Original article
Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: A Retrospective Registry-Based Study Using the Korean Organ Transplant Registry (KOTRY)
Sang-Hoon Kim BCDEF 1, Shin Hwang ABG 1*, Bong-Wan Kim ABG 2, Dong Jin Joo ABD 3, Kwang-Woong Lee ABD 4, Gyu-Seong Choi AD 5, Je Ho Ryu ABD 6, Dong-Sik Kim ABD 7, Dongho Choi ABD 8, Jai Young Cho ABD 9, Young Kyoung You ABD 10, Dongho Choi ABD 11, Tae-Seok Kim ABD 12, PyoungJae Park ABD 13DOI: 10.12659/AOT.949241
Ann Transplant 2025; 30:e949241
Table 4 Literature review of liver transplantation for combined hepatocellular-cholangiocarcinoma.
| Study | Country | Study period | N | Follow-up months (median) | Patient mortality | Tumor recurrence | OS | DFS | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 3-year | 5-year | 1-year | 3-year | 5-year | |||||||
| Chan 2007 | Hong Kong | 1994–2005 | 3 | 25 | 1 (33.3) | 100 | 66.7 | |||||
| Maganty 2010 | USA | 1994–2009 | 3 | 37.5 | 2 (66.7) | 2 (66.7) | 33.3 | 33.3 | 33.3 | 33.3 | 33.3 | 33.3 |
| Panjala 2010 | USA | 1998–2008 | 12 | 11.1 | 7 (58.0) | 79 | 66 | 16 | ||||
| Harring 2011 | USA | 1998–2011 | 5 | 26.2 | 1 (20.0) | 1 (20.0) | 100 | 50 | 50 | 100 | 50 | 50 |
| Park 2013 | Korea | 1999–2009 | 15 | 7 (46.6) | 7 (46.6) | 66.7 | 60 | 60 | 60 | 53.3 | 53.3 | |
| Groeschl 2013 | USA | 1973–2007 | 19 | 89 | 48 | |||||||
| USA | 1994–2007 | 65 | 33 (50.8) | 75 | 45 | 28 | ||||||
| Song 2013 | Korea | 1995–2012 | 8 | 34.5 | 4 (50.0) | 5 (62.5) | 75.0 | 50.0 | 50.0 | 50.0 | 37.5 | 37.5 |
| Garancini 2014 | Italy | 1988–2009 | 61 | 86.6 | 62.8 | 41.1 | ||||||
| Wu 2015 | China | 2000–2011 | 21 | 11 (52.4) | 64 | 39 | 39 | 64 | 30 | 30 | ||
| Itoh 2015 | Japan | 1999–2014 | 8 | 3 (37.5) | 2 (20.0) | 87.5 | 72.9 | 72.9 | 85.7 | 85.7 | 85.7 | |
| Wu 2016 | China | 2006–2014 | 8 | 4 | 75 | |||||||
| Vilchez 2016 | USA | 1994–2013 | 94 | 82 | 47 | 40 | ||||||
| Chang 2017 | Taiwan | 2006–2014 | 10 | 23.9 | 4 (40.0) | 90.0 | 61.7 | 41.1 | 80.0 | 46.7 | 46.7 | |
| Jung 2017 | Korea | 2005–2014 | 32 | 48.6 (mean) | 11 (34.4) | 12 (37.5) | 95 | 72.5 | 66 | |||
| Lunsford 2018 | USA | 1984–2015 | 12 | 27.9 | 6 (50.0) | 75 | 54 | 42 | 66 | 42 | 42 | |
| Ito 2020 | Japan | 2005–2018 | 4 | 40 | 1 (25.0) | 1 (25.0) | 100 | 66.7 | 66.7 | 75.0 | 75.0 | 75.0 |
| Dageforde 2020 | USA | 2009–2017 | 99 | 35 (35.3) | 84 | 68 | 58.4 | |||||
| Jaradat 2021 | Germany | 2001–2018 | 19 | 42.5 | 11 (57.9) | 11 (64.7) | 57.1 | 38.1 | ||||
| Chen 2022 | China | 2004–2015 | 60 | 86.7 | 68.3 | 56.6 | ||||||
| N – patient number; OS – overall survival; DFS – diseas-free survival. | ||||||||||||